<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04680468</url>
  </required_header>
  <id_info>
    <org_study_id>UPCC 37420</org_study_id>
    <secondary_id>IRB#844252</secondary_id>
    <nct_id>NCT04680468</nct_id>
  </id_info>
  <brief_title>Study of Belantamab Mafodotin as Pre- and Post-autologous Stem Cell Transplant and Maintenance for Multiple Myeloma</brief_title>
  <official_title>Phase 2 Study of Belantamab Mafodotin as Pre- and Post-autologous Stem Cell Transplant Consolidation and Maintenance for Multiple Myeloma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Abramson Cancer Center of the University of Pennsylvania</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Abramson Cancer Center of the University of Pennsylvania</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a single-institution, single-arm, phase 2 study in which belantamab mafodotin&#xD;
      (GSK2857916), an antibody-drug conjugate targeting B-cell maturation antigen (BCMA), will be&#xD;
      administered to patients with multiple myeloma prior to and following high-dose melphalan and&#xD;
      autologous stem cell transplantation (ASCT), in conjunction with standard lenalidomide&#xD;
      maintenance. We hypothesize that administration of belantamab mafodotin as part of autologous&#xD;
      stem cell transplant consolidation and maintenance will be safe, well tolerated, and&#xD;
      efficacious in comparison to historical data.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 25, 2021</start_date>
  <completion_date type="Anticipated">July 11, 2026</completion_date>
  <primary_completion_date type="Anticipated">July 11, 2026</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>MRD (minimal residual disease) negativity rate</measure>
    <time_frame>12 months post-ASCT</time_frame>
    <description>Percentage of participants who have achieved minimal residual disease (MRD) negativity by next-generation sequencing (NGS) at 12 months post-autologous stem cell transplant (ASCT)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Frequency of treatment-related adverse events</measure>
    <time_frame>through study completion, approximately 3 years</time_frame>
    <description>Percentage of participants who develop adverse and serious adverse events, including ocular adverse events.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dose reductions</measure>
    <time_frame>through study completion, approximately 3 years</time_frame>
    <description>The percentage of participants who require reduction of the dose of belantamab mafodotin will be assessed</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dose delays</measure>
    <time_frame>through study completion, approximately 3 years</time_frame>
    <description>The percentage of participants who require a delay in dosing of belantamab mafodotin will be assessed</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MRD Negativity Rate</measure>
    <time_frame>at 3 and 24 months post-ASCT</time_frame>
    <description>Percentage of participants who have achieved minimal residual disease (MRD) negativity by next-generation sequencing (NGS) at 3 and 24 months post-autologous stem cell transplant (ASCT)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall response rate</measure>
    <time_frame>through study completion, approximately 3 years</time_frame>
    <description>Percentage of participants who achieve partial response (PR) or better, as assessed by International Myeloma Working Group (IMWG) criteria.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Very good partial response (VGPR) or better rate</measure>
    <time_frame>through study completion, approximately 3 years</time_frame>
    <description>Percentage of participants who achieve VGPR or better, as assessed by IMWG criteria.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Complete response (CR) or better rate</measure>
    <time_frame>through study completion, approximately 3 years</time_frame>
    <description>Percentage of participants who achieve CR or stringent CR, as assessed by IMWG criteria.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival</measure>
    <time_frame>through study completion, approximately 3 years</time_frame>
    <description>Time from enrollment until progression of disease by IMWG criteria, or death, whichever occurs first</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>through study completion, approximately 3 years</time_frame>
    <description>Time from enrollment until death from any cause</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stem cell yield</measure>
    <time_frame>Following stem cell mobilization, about 6 weeks after enrollment</time_frame>
    <description>The number of days required to collect sufficient autologous peripheral blood stem cells to proceed to ASCT will be assessed</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stem cell collection days</measure>
    <time_frame>Following stem cell mobilization, about 6 weeks after enrollment</time_frame>
    <description>: The number of days required to collect sufficient autologous peripheral blood stem cells to proceed to ASCT will be assessed</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hematopoietic reconstitution post-ASCT</measure>
    <time_frame>up to 30 days post-ASCT</time_frame>
    <description>The number of days until neutrophil and platelet recovery post-ASCT (defined as absolute neutrophil count &gt;1000 cells/mcl and platelet count &gt;50000 cells/mcl, respectively) will be assessed</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Health-related quality of life (HRQoL) as assessed by Functional Assessment of Cancer Therapy - Multiple Myeloma (FACT-MM) questionnaire</measure>
    <time_frame>baseline through study completion, approximately 3 years.</time_frame>
    <description>The FACT-MM questionnaire is a 41 item questionnaire measuring physical, social/family, emotional, and functional well-being, as well as additional concerns</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">47</enrollment>
  <condition>Myeloma</condition>
  <arm_group>
    <arm_group_label>Belantamab mafodotin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive Belantamab mafodotin 2.5 mg/kg by intravenous infusion on day -42 relative to autologous stem cell infusion (day 0), on day +60, and every 90 days thereafter, for up to 2 years following ASCT.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Belantamab mafodotin</intervention_name>
    <description>2.5 mg/kg IV</description>
    <arm_group_label>Belantamab mafodotin</arm_group_label>
    <other_name>GSK2857916</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Subjects must have started therapy for active multiple myeloma within 12 months of&#xD;
             enrollment.&#xD;
&#xD;
          -  Subjects must have an ECOG performance status of 0-2.&#xD;
&#xD;
          -  Have received no more than 2 prior lines of induction therapy (induction regimen not&#xD;
             specified by protocol), with no prior progressive disease by International Myeloma&#xD;
             Working Group (IMWG) criteria.&#xD;
&#xD;
          -  Must be in at least a partial response (PR) but not in a stringent complete response&#xD;
             (sCR) after at least 4 cycles of induction therapy, per IMWG consensus criteria.&#xD;
&#xD;
          -  Eligible by institutional criteria to receive melphalan at a dose of 200 mg/m2.&#xD;
&#xD;
          -  Eligible to receive lenalidomide maintenance therapy post-ASCT.&#xD;
&#xD;
          -  Adequate bone marrow and organ function at enrollment&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Participant must not have used an investigational drug or approved systemic&#xD;
             anti-myeloma therapy (including systemic steroids) within 14 days or five half-lives,&#xD;
             whichever is shorter, preceding the first dose of study drug.&#xD;
&#xD;
          -  Participant must not have received treatment with a monoclonal antibody within 28 days&#xD;
             of receiving the first dose of study drug&#xD;
&#xD;
          -  Participant must not be simultaneously enrolled in any interventional clinical trial&#xD;
&#xD;
          -  Participant must not have amyloidosis or POEMS syndrome.&#xD;
&#xD;
          -  Participants must not be pregnant or lactating.&#xD;
&#xD;
          -  Participant must not have current unstable liver or biliary disease defined by the&#xD;
             presence of ascites, encephalopathy, coagulopathy, severe hypoalbuminemia, esophageal&#xD;
             or gastric varices, persistent jaundice, or cirrhosis. Note: Stable non-cirrhotic&#xD;
             chronic liver disease (including Gilbert's syndrome or asymptomatic gallstones) or&#xD;
             hepatobiliary involvement of malignancy is acceptable if otherwise meets entry&#xD;
             criteria&#xD;
&#xD;
          -  Participant must not have any evidence of active mucosal or internal bleeding&#xD;
&#xD;
          -  History of an active renal condition (infection, requirement for dialysis or any other&#xD;
             condition that could affect subject's safety). Subjects with isolated proteinuria&#xD;
             resulting from MM are eligible, provided they fulfill criteria given in Section 6.1.&#xD;
&#xD;
          -  Participant must not have evidence of cardiovascular risk&#xD;
&#xD;
          -  Participants must not have any serious and/or unstable pre-existing medical,&#xD;
             psychiatric disorder, or other conditions (including lab abnormalities) that could&#xD;
             interfere with subject's safety, obtaining informed consent or compliance to the study&#xD;
             procedures.&#xD;
&#xD;
          -  Participant must not have invasive malignancies other than disease under study, unless&#xD;
             the second malignancy has been definitively treated or has been medically stable for&#xD;
             at least 2 years and, in the opinion of the principal investigator, will not affect&#xD;
             the evaluation of the effects of clinical trial treatment.&#xD;
&#xD;
          -  Participants must not have an active infection requiring antibiotic treatment.&#xD;
&#xD;
          -  Any major surgery within the last 4 weeks prior to enrollment.&#xD;
&#xD;
          -  Participant must not have current corneal epithelial disease except mild changes in&#xD;
             corneal epithelium&#xD;
&#xD;
          -  Participant must not have known immediate or delayed hypersensitivity reaction or&#xD;
             idiosyncratic reactions to belantamab mafodotin or drugs chemically related to&#xD;
             belantamab mafodotin, or any of the components of the study treatment&#xD;
&#xD;
          -  Participant must not have evidence for active hepatitis B infection (i.e. positive&#xD;
             hepatitis B surface antigen or nucleic acid-based testing) at screening or within 3&#xD;
             months prior to first dose of belantamab mafodotin. Subjects with positive testing for&#xD;
             hepatitis B core antibody but no evidence for active infection by nucleic acid-based&#xD;
             testing may enroll if they agree to hepatitis B prophylactic therapy and monitoring&#xD;
             for HBV re-activation for the duration of the study.&#xD;
&#xD;
          -  Participant must not have positive hepatitis C antibody test result or positive&#xD;
             hepatitis C RNA test result at screening or within 3 months prior to first dose of&#xD;
             study treatment. NOTE: Participants with positive hepatitis C antibody due to prior&#xD;
             resolved disease can be enrolled, only if a confirmatory negative hepatitis C RNA test&#xD;
             is obtained.&#xD;
&#xD;
          -  Participant must not have evidence of active HIV infection. Participants with positive&#xD;
             HIV serologies who are on stable active anti-retroviral therapy, have CD4 count &gt; 200&#xD;
             cells/ÂµL, and have no detectable HIV virus by nucleic acid-based testing at screening&#xD;
             or within 3 months prior to first dose of study drug may be eligible after discussion&#xD;
             with medical director and/or principal investigator.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Adam Cohen, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Pennsylvania</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Harjeet Sembhi</last_name>
    <phone>215-220-9688</phone>
    <email>harjeet.sembhi@pennmedicine.upenn.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Adam Cohen, MD</last_name>
    <phone>215-615-7362</phone>
    <email>adam.cohen@pennmedicine.upenn.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Abramson Cancer Center at University of Pennsylvania</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>December 2, 2020</study_first_submitted>
  <study_first_submitted_qc>December 17, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 23, 2020</study_first_posted>
  <last_update_submitted>May 25, 2021</last_update_submitted>
  <last_update_submitted_qc>May 25, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 27, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Neoplasms, Plasma Cell</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

